Myelofibrosis: Novel Treatment Strategies and Combination Therapies

After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).

For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.

A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.

After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.

From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.

Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.

A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.

In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.